Previous close | 0.0610 |
Open | 0.0610 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0610 - 0.0610 |
52-week range | 0.0160 - 0.2470 |
Volume | |
Avg. volume | 15,917 |
Market cap | 623,145 |
Beta (5Y monthly) | -0.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WEST PALM BEACH, FL, March 28, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today reported its financial and operational results for the fiscal year ended December 31, 2023. The year was marked by robust revenue growth, significant improvements in gross margins, and a strategic focus on expanding produ
This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers. WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce the seamless integration of its digital medicine assessments with one of the nation’s top E
25% Y-O-Y Revenue Growth in Q3 2023 Compared to Q3 2022 and 51% Increase in Gross Profit. ●In Q3 2023, QHSLab generated $336,407 in revenues, reflecting a notable 25% year-over-year increase from the $269,323 reported in Q3 2022. ●Achieved a 55% gross margin over the nine months ending September 30, 2023, representing a 551-basis point growth in gross profit compared to the same period in 2022, and realized a remarkable 51% increase in gross profit, reaching $189,510 in the three months ended Se